Germany, Sept. 11 -- Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, the European Investment Bank (EIB), and the European Commission's Health Emergency Preparedness and Response Authority (DG HERA), announced a €30 million financing agreement to advance further clinical development of Ethris' portfolio of respiratory mRNA products.This includes the company's lead mRNA-based candidate, ETH47, focusing on asthma and chronic obstructive pulmonary disease (COPD), as well as additional programmes, notably ETH52 and ETH53, focusing on mucosal influenza vaccines and pandemic preparedness. The signing ceremony took place at Ethris' headquarters in Munich.ETH47 is currently being ev...